Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(17)

Published: Feb. 26, 2024

As an indispensable part of the human sensory system, visual acuity may be impaired and even develop into irreversible blindness due to various ocular pathologies. Among diseases, fundus neovascularization diseases (FNDs) are prominent etiologies impairment worldwide. Intravitreal injection anti-vascular endothelial growth factor drugs remains primary therapy but is hurdled by common complications incomplete potency. To renovate current therapeutic modalities, nanomedicine emerged as times required, which endowed with advanced capabilities, able fulfill effective drug delivery achieve precise release control, thus further improving effect. This review provides a comprehensive summary advances in for FND management from state-of-the-art studies. First, modalities FNDs thoroughly introduced, focusing on key challenges delivery. Second, nanocarriers comprehensively reviewed posterior based nanostructures: polymer-based nanocarriers, lipid-based inorganic nanoparticles. Thirdly, characteristics microenvironment, their pathological changes during FNDs, corresponding strategies constructing smart elaborated. Furthermore, prospects discussed.

Language: Английский

---

Light-responsive polymeric nanoparticles for retinal drug delivery: design cues, challenges and future perspectives

Heliyon, Journal Year: 2024, Volume and Issue: 10(5), P. e26616 - e26616

Published: Feb. 18, 2024

A multitude of sight-threatening retinal diseases, affecting hundreds millions around the globe, lack effective pharmacological treatments due to ocular barriers and common drug delivery limitations. Polymeric nanoparticles (PNPs) are versatile carriers with sustained release profiles tunable physicochemical properties which have been explored for both anterior posterior tissues. PNPs can incorporate a wide range drugs overcome challenges conventional delivery. Moreover, be engineered respond specific stimuli such as ultraviolet, visible, or near-infrared light, allow precise spatiotemporal control release, enabling tailored treatment regimens reducing number required administrations. The objective this study is emphasize therapeutic potential light-triggered drug-loaded polymeric treat diseases through an exploration pathologies, in delivery, current production methodologies recent applications. Despite challenges, light-responsive hold promise substantially enhancing landscape aiming improved quality life patients.

Language: Английский

---

Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

Ocular surface chemical injuries often result in permanent visual impairment and necessitate complex, long-term treatments. Immediate extensive irrigation serves as the first-line intervention, followed by various therapeutic protocols applied throughout different stages of condition. To optimize outcomes, conventional regimens increasingly incorporate biological agents surgical techniques. In recent years, nanotechnology has made significant strides, revolutionizing management ocular enabling sustained drug release, enhancing treatment efficacy, minimizing side effects. This review provides a comprehensive analysis etiology, epidemiology, classification, therapies for burns, with special focus on nanotechnology-based delivery systems managing injuries. Twelve categories nanocarrier platforms are examined, including liposomes, nanoemulsions, nanomicelles, nanowafers, nanostructured lipid carriers, nanoparticles, hydrogels, dendrimers, nanocomplexes, nanofibers, nanozymes, nanocomposite materials, highlighting their advantages targeted delivery, biocompatibility, improved healing efficacy. Additionally, current challenges limitations field discussed future potential treating diseases is explored. presents most examination this topic to date, aiming link advancements broader strategies.

Language: Английский

---

Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases

Pharmaceutics, Journal Year: 2021, Volume and Issue: 13(2), P. 288 - 288

Published: Feb. 22, 2021

Suprachoroidal drug delivery technology has advanced rapidly and emerged as a promising administration route for variety of therapeutic candidates, in order to target multiple ocular diseases, ranging from neovascular age-related macular degeneration choroidal melanoma. This review summarizes the latest preclinical clinical progress suprachoroidal agents, including small molecule suspensions, polymeric entrapped molecules, gene therapy (viral nonviral nanoparticles), viral nanoparticle conjugates (VNCs), cell therapy. Formulation customization is critical achieving favorable pharmacokinetics, sustained release profiles have been repeatedly observed suspensions formulations. Novel agents such therapy, well VNCs, demonstrated promise animal studies. Several these suprachoroidally-administered therapies assessed trials, triamcinolone acetonide axitinib, vector RGX-314 VNC AU-011. With continued research optimization, coupled with customized formulations, may address large unmet needs ophthalmology, targeting affected tissues novel efficacy benefits, compartmentalizing away unaffected safety durability relieve treatment burden noted current agents.

Language: Английский

---

Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization

International Journal of Pharmaceutics, Journal Year: 2022, Volume and Issue: 620, P. 121725 - 121725

Published: April 9, 2022

Choroidal neovascularization (CNV) is a prevalent vision-threatening vascular disorder in aging population. CNV associated with several diseases the posterior segment of eye such as age-related macular degeneration (AMD). In this study we developed sunitinib-loaded liposomes to block signalling pathway through inhibition tyrosine kinase endothelial growth factor receptors (VEGFRs). Liposomal sunitinib formulations were prepared by thin film hydration method and studied for their encapsulation efficiency (EE), loading capacity (LC) drug release profile buffer andvitreous. Our finding showed that (mean size 104 nm) could effectively entrap (EE ≈ 95%) at relatively high (LC 5%) over least 3 days. Intravitreal revealed inhibitory effect on established laser-induced mouse model while intravitreal injection solubilized cyclodextrin was inefficient management neovascularization. Accordingly, liposomal promising delivery system should be further inhibit related AMD.

Language: Английский

---

Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities

Journal of Nanobiotechnology, Journal Year: 2022, Volume and Issue: 20(1)

Published: Dec. 3, 2022

Abstract Inherited Retinal Diseases (IRDs) are considered one of the leading causes blindness worldwide. However, majority them still lack a safe and effective treatment due to their complexity genetic heterogeneity. Recently, gene therapy is gaining importance as an efficient strategy address IRDs which were previously incurable. The development clustered regularly-interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) system has strongly empowered field therapy. successful modifications rely on delivery CRISPR-Cas9 components into complex three-dimensional (3D) architecture human retinal tissue. Intriguing findings in nanoparticles (NPs) meet all criteria required for have made great contribution toward its therapeutic applications. In addition, exploiting induced pluripotent stem cell (iPSC) technology vitro 3D organoids paved way prospective clinical trials treating IRDs. This review highlights important advances NP-based therapy, system, iPSC-derived with focus Collectively, these studies establish multidisciplinary approach by integrating nanomedicine technologies demonstrate utility retina developing therapies

Language: Английский

---

Reactive oxygen species‐responsive mitochondria‐targeted liposomal quercetin attenuates retinal ischemia–reperfusion injury via regulating SIRT1/FOXO3A and p38 MAPK signaling pathways

Bioengineering & Translational Medicine, Journal Year: 2022, Volume and Issue: 8(3)

Published: Dec. 1, 2022

Retinal ischemia-reperfusion (RIR) injury is involved in the pathogenesis of various vision-threatening diseases. The overproduction reactive oxygen species (ROS) thought to be main cause RIR injury. A variety natural products, including quercetin (Que), exhibit potent antioxidant activity. However, lack an efficient delivery system for hydrophobic Que and presence intraocular barriers limit effective retinal clinical settings. In this study, we encapsulated into ROS-responsive mitochondria-targeted liposomes (abbreviated Que@TPP-ROS-Lips) achieve sustained retina. intracellular uptake, lysosome escape ability, mitochondria targeting ability Que@TPP-ROS-Lips were evaluated R28 cells. Treating cells with significantly ameliorated decrease ATP content, ROS generation, increase release lactate dehydrogenase vitro oxygen-glucose deprivation (OGD) model ischemia. a rat model, intravitreal injection 24 h after inducing ischemia enhanced electrophysiological recovery reduced neuroinflammation, oxidative stress, apoptosis. taken up by retina at least 14 days administration. Molecular docking functional biological experiments revealed that targets FOXO3A inhibit stress inflammation. also partially inhibited p38 MAPK signaling pathway, which contributes conclusion, our new platform drug shows promise treatment promotes application products.

Language: Английский

---

Selective drug delivery to the retinal cells: Biological barriers and avenues

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 361, P. 1 - 19

Published: July 27, 2023

Retinal drug delivery is a challenging, but important task, because most retinal diseases are still without any proper therapy. Drug to the retina hampered by anatomical and physiological barriers resulting in minimal bioavailability after topical ocular systemic administrations. Intravitreal injections current method-of-choice delivery, these show short duration of action for small molecules low target many protein, gene based drugs nanomedicines. State-of-art systems on prolonged retention, controlled release physical features (e.g. size charge). However, not cell-specific approaches do facilitate intracellular modern biological proteins, RNA medicines, editing). In this focused review we highlight factors mechanisms that form basis selective future. Therefore, presenting knowledge related membrane transporters, receptors targeting ligands relation nanomedicines, conjugates, extracellular vesicles, melanin binding. These issues discussed light structure cell types as well future prospects field. Unlike some other fields targeted cancer research), technologies have been rarely studied, even though may be more feasible local administration into eye.

Language: Английский

---

Platinum Nanozymes Counteract Photoreceptor Degeneration and Retina Inflammation in a Light-Damage Model of Age-Related Macular Degeneration

ACS Nano, Journal Year: 2023, Volume and Issue: 17(22), P. 22800 - 22820

Published: Nov. 7, 2023

Degeneration of photoreceptors in age-related macular degeneration (AMD) is associated with oxidative stress due to the intense aerobic metabolism rods and cones that if not properly counterbalanced by endogenous antioxidant mechanisms can precipitate photoreceptor degeneration. In spite being a priority eye disease for its high incidence elderly, no effective treatments AMD exist. While systemic administration antioxidants has been unsuccessful slowing down degeneration, locally administered rare-earth nanoparticles were shown be preventing retinal photo-oxidative damage. However, because inherent problems dispersion biological media, limited power, short lifetimes, these NPs are still confined preclinical stage. Here we propose platinum (PtNPs), potent nanozymes, as therapeutic tool AMD. PtNPs exhibit catalytic activity at minimal concentrations protect primary neurons against insults ensuing apoptosis. We tested efficacy intravitreally injected or mitigating light damage produced dark-reared albino Sprague–Dawley rats vivo electroretinography (ERG) ex retina morphology electrophysiology. found both preventive postlesional increased amplitude ERG responses stimuli. Ex recordings demonstrated selective preservation ON ganglion cell stimulation lesioned retinas treated PtNPs. after significantly preserved number inhibited inflammatory response while treatment had milder effect. The data indicate effectively break vicious cycle linking stress, inflammation exerting anti-inflammatory actions. survival visual performances degenerated retinas, together their biocompatibility, make potential strategy cure

Language: Английский

---

Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy

Drug Delivery and Translational Research, Journal Year: 2023, Volume and Issue: 13(6), P. 1675 - 1698

Published: Jan. 11, 2023

Language: Английский

---